Melanoma & Skin Cancer | Specialty

The OncLive Melanoma & Skin Cancer condition center page is a comprehensive resource for clinical news and expert insights on various types of skin cancers, including melanoma, basal cell carcinoma, and more. This section features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research in melanoma and other skin cancers.

Overall Survival Is a Highly Relevant but Potentially Problematic End Point in Randomized Trials

December 21st 2022

Overall survival is a critically relevant end point in randomized oncology clinical trials, but its interpretation is often not as straightforward as some may wish to acknowledge.

Dr. Contreras on Neoadjuvant Therapies in Basal Cell Carcinoma and Cutaneous Squamous Cell Carcinoma

December 19th 2022

Carlo Contreras, MD, discusses areas of planned and ongoing research with neoadjuvant therapies in basal cell carcinoma and cutaneous squamous cell carcinoma.

Dr. Verschraegen on the Need to Address TRAEs of Immunotherapy in Melanoma

December 9th 2022

Claire F. Verschraegen, MD, discusses the need to improve the management of treatment-related adverse effects of immunotherapy in melanoma.

Lifileucel Induces Response in Metastatic Melanoma Independent of Number of IL-2 Doses Received

December 8th 2022

Lifileucel achieved safety and efficacy irrespective of the number of aldesleukin doses administered to patients with advanced melanoma.

Pembrolizumab Appears Safe Across Melanoma, NSCLC, RCC in Pooled Analysis

December 8th 2022

Pembrolizumab induced treatment-related adverse effects that were generally mild or moderate in severity, according to finding from a pooled analysis of more than 4000 patients with melanoma, non–small cell lung cancer, or renal cell carcinoma.

RP1 Plus Nivolumab Elicits Responses in Melanoma After Progression on Anti–PD-1 Therapy

December 7th 2022

The combination of vusolimogene oderparepvec and nivolumab generated promising responses in patients with cutaneous melanoma who failed previous anti–PD-1 therapy, according to initial data from the phase 2 IGNYTE trial.

Dr. Patel on Adjuvant Nivolumab Plus Ipilimumab Regimens in Stage IV Melanoma

December 6th 2022

Sapna Patel, MD, discusses the evaluation of adjuvant nivolumab plus ipilimumab in stage IV metastatic melanoma with no evidence of disease.

Neoadjuvant Vidutolimod Plus Nivolumab Demonstrates Favorable Efficacy, Tolerability in Resectable Melanoma

December 5th 2022

The combination of neoadjuvant vidutolimod and nivolumab elicited high response rates and was well tolerated in patients with high-risk, resectable melanoma, according to final results from a phase 2 trial.

Nivolumab/Ipilimumab Combo Elicits 100% ORR in Checkpoint Inhibitor–Naïve Merkel Cell Carcinoma

November 29th 2022

The combination of nivolumab and ipilimumab, irrespective of the addition of stereotactic body radiation therapy, generated an overall response rate of 100% in patients with Merkel cell carcinoma who were naïve to immune checkpoint inhibitors.

ARRY-614 Plus Immune Checkpoint Inhibition Can Induce Durable Responses in Advanced Solid Tumors

November 28th 2022

The combination of the p38 MAPK inhibitor ARRY-614 plus nivolumab with or without ipilimumab was well tolerated and elicited disease control in high-risk, PD-(L)1–refractory patients with advanced solid tumors.

Adjuvant Nivolumab Displays Real-world Benefits in Resected Stage IIIA Melanoma

November 27th 2022

Adjuvant nivolumab produced survival benefits in patients with resected stage IIIA melanoma, where a significant portion of patients were recurrence free at a median follow-up of over 20 months.

Updates from Melanoma Trials Demonstrate New Roles for Adjuvant/Neoadjuvant Treatment

November 23rd 2022

Sapna Patel, MD, reviews several key studies across stages of melanoma and emerging targeted therapies for patients with BRAF mutations.

Iovance to Address FDA Requests for BLA of Lifileucel in Advanced Melanoma

November 21st 2022

After receiving FDA feedback regarding supplemental assay validation information and comparability data for lifileucel in advanced melanoma, Iovance Biotherapeutics will address these comments and plans to complete its rolling biologics license application submission during the first quarter of 2023.

FDA Grants Orphan Drug Designation to AVS100 for Stage IIB-IV Melanoma

November 17th 2022

The FDA has granted an orphan drug designation to the highly specific HDAC6 inhibitor AVS100 for the treatment of patients with stage IIB to IV melanoma.

Sotigalimab/Pembrolizumab Combo Continues to Show Clinical Activity in Frontline Melanoma

November 16th 2022

The combination of sotigalimab and pembrolizumab showed encouraging antitumor activity and was well tolerated in the frontline setting of patients with metastatic melanoma.

Multidisciplinary Discussions Shape Systemic and Surgical Skin Cancer Treatment

November 15th 2022

Future advances in melanoma and other skin cancers should focus on team-oriented care and increasingly informed treatment sequencing regarding the roles of immunotherapy, targeted therapy, and surgery.

Dr. Carvajal on Unique Prognostic Factors in Uveal Melanoma

November 11th 2022

Richard D. Carvajal, MD, discusses the prognostic factors of uveal melanoma that differentiate it from other subsets of melanoma.

Every Patient With Metastatic Melanoma “Deserves a Shot at Nivolumab/Ipilimumab,” Weber Says

November 10th 2022

The combination of nivolumab and ipilimumab have shown overall survival benefit in patients with metastatic melanoma, according to long-term follow-up data, and other studies’ results highlight the efficacy and toxicity benefits of different sequences of the combination.

Looking Ahead: Unmet Needs for the Treatment of BCC

November 9th 2022

Nikhil Khushalani, MD, comments on upcoming treatment advances he looks forward to for patients with BCC.

DREAMSeq Trial Clarifies Treatment Sequencing in BRAF V600–Mutant Melanoma

November 8th 2022

Immunotherapy followed by targeted therapy has emerged as the new standard of care for patients with melanoma with BRAF V600 mutations.